psilocybin (COMP360) / Compass Pathways 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345678910111213...1314»
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Enzymatic route toward 6-methylated baeocystin and psilocybin. (Pubmed Central) -  Aug 23, 2020   
    N-methylation was catalyzed by PsiM. We further present an in silico structural model of PsiM that revealed a well-conserved SAM-binding core along with peripheral non-conserved elements that likely govern substrate preferences.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] The effect of psilocybin on sleep (Stream 2) -  Aug 16, 2020 - Abstract #ESRS2020ESRS_773;    
    P1/2
    Contrary to our expectations, our data did not provide evidence for sleep-related neuroplastic changes. This might be due to longer pharmacological dynamics of psilocybin compared to other psychedelic drugs promoting SWA, e.g. ketamine or ayahuyasca.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] Sleep as resource of mental health (Stream 2) -  Aug 16, 2020 - Abstract #ESRS2020ESRS_769;    
    Finally, Jana Koprivova will present a study examing the effects of the psychedelic drug psilocybin, a new antidepressant approach, on subjective and objective sleep characteristics. She proposes that part of the antidepressant drug actions may rely on changes of REM sleep and possibly also sleep-related neuroplastic changes.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Cessation and reduction in alcohol consumption and misuse after psychedelic use. (Pubmed Central) -  Aug 13, 2020   
    Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption...Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress. Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. (Pubmed Central) -  Aug 13, 2020   
    Owing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin...It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. (Pubmed Central) -  Aug 11, 2020   
    These findings highlight the interactions between non-pharmacological and pharmacological factors, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes. A better comprehension of mechanisms underlying most beneficial psychedelic experiences may guide therapeutic interventions across numerous mental conditions in the form of psychedelic-assisted applications.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Dynamic coupling of whole-brain neuronal and neurotransmitter systems. (Pubmed Central) -  Aug 11, 2020   
    This advance provides an understanding of why psilocybin is showing considerable promise as a therapeutic intervention for neuropsychiatric disorders including depression, anxiety, and addiction. Overall, these insights demonstrate that the whole-brain mutual coupling between the neuronal and the neurotransmission systems is essential for understanding the remarkable flexibility of human brain function despite having to rely on fixed anatomical connectivity.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Trial completion date, Trial primary completion date:  The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (clinicaltrials.gov) -  Aug 11, 2020   
    P2,  N=216, Recruiting, 
    Overall, these insights demonstrate that the whole-brain mutual coupling between the neuronal and the neurotransmission systems is essential for understanding the remarkable flexibility of human brain function despite having to rely on fixed anatomical connectivity. Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Aug 2020 --> May 2021
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    Journal:  Psychedelic Research and the Need for Transparency: Polishing Alice's Looking Glass. (Pubmed Central) -  Aug 6, 2020   
    We end with a discussion of researcher intention and the value of actively deciding to abide by higher scientific standards. We can build a rigorous, transparent, replicable psychedelic science by using Open Science to understand psychedelics' potential as they re-enter science and society.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain (Poster Area) -  Aug 5, 2020 - Abstract #ECNP2020ECNP_1132;    
    We find that psilocybin intervention increases the synaptic marker SV2A in hippocampus and PFC 7 day after and decreases the 5-HT2A R in the hippocampus 1 day, but not 7 days after. The increase in synaptic density may be an important mechanism of action to explain the rapid and long-lasting antidepressive effects of psilocybin described in some studies in patients with treatment-resistant depression.
  • ||||||||||  ketamine / Generic mfg., psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] A single dose of LSD facilitates long-lasting fear erasure in mice (Poster Area) -  Aug 5, 2020 - Abstract #ECNP2020ECNP_938;    
    However, we found that the LSD-induced increase in HTR (typically associated with the acute effects of serotonergic hallucinogens) remained unaffected by the mutation [interaction: F(1,16)=1.129, p=0.3038; treatment: F(1,16)=188.6, p<0.0001].Our findings suggest that psychedelics reinstate juvenile-like plasticity in the adult brain and can produce enduring therapeutic outcomes at the behavioral level. Interestingly, these effects seem to depend on the antidepressant-binding site of TRKB, which may point at a common mechanism for antidepressant action.
  • ||||||||||  psilocybin (COMP360) / Compass Pathways
    [VIRTUAL] Acute effects of psilocybin on glutamate concentration levels, functional connectivity and subjective state (Poster Area) -  Aug 5, 2020 - Abstract #ECNP2020ECNP_558;    
    Our data demonstrate that psilocybin acutely induces region dependent alterations in glutamate that correlate with established biological and behavioral changes during the psychedelic state, providing further insights into potential underlying neurobiological mechanisms. Importantly, as enhanced glu-mPFC has been associated with increased neurogenesis in rodent models, and acute feelings of ego dissolution and DMN activity have been correlated with long-term increases in subjective well-being, our data provide a neurochemical basis for how these substances may be giving rise to therapeutic effects as witnessed in ongoing clinical trials.